Gene Therapy: From Concept to Clinical Reality

Gene therapy—the treatment or prevention of disease by modifying an individual's genetic material—has moved from science fiction to clinical reality over the past decade. Multiple gene therapies have now received regulatory approval, and hundreds more are in clinical trials, offering transformative treatments for previously incurable diseases.

Gene Therapy Approaches

Several distinct gene therapy strategies are now in clinical use. Gene addition (or gene augmentation) delivers a working copy of a defective gene to supplement or replace the non-functional native copy. This approach works for diseases caused by loss-of-function mutations. Gene silencing uses antisense oligonucleotides, siRNA, or other approaches to reduce expression of a harmful gene. Gene editing using CRISPR-Cas9 or other nucleases precisely modifies specific DNA sequences—enabling correction of mutations, addition of therapeutic genes, or disruption of disease-causing sequences.

Delivery Vectors

Effective gene therapy requires efficient delivery of genetic material into target cells. Adeno-associated viruses (AAVs) are the most commonly used viral vectors for in vivo gene therapy, offering efficient transduction of diverse tissues with minimal pathogenicity. Different AAV serotypes (AAV2, AAV5, AAV8, AAV9, etc.) show distinct tissue tropism. Lentiviruses are retroviruses that integrate into the host genome, making them suitable for ex vivo gene therapy in dividing cells like hematopoietic stem cells. Lipid nanoparticles (LNPs) are non-viral delivery vehicles used successfully in mRNA vaccines and some gene therapy applications.

Approved Gene Therapies

Several landmark gene therapies have received regulatory approval. Luxturna treats inherited retinal dystrophies caused by RPE65 mutations, using a single injection to restore functional vision. Zolgensma treats spinal muscular atrophy (SMA) type 1 in children under 2 years of age with a single intravenous infusion. Hemgenix treats hemophilia B with a single infusion providing sustained factor IX production. Casgevy, using CRISPR-Cas9, treats sickle cell disease and beta-thalassemia.

Challenges and Future Directions

Gene therapy faces challenges including high manufacturing costs, immunogenicity of viral vectors, durability of effect, and difficulty treating diseases affecting tissues that are hard to access. The field is advancing rapidly, with base editing and prime editing offering increasingly precise correction capabilities and new delivery approaches expanding treatable conditions.

For more on gene therapy and genomic medicine, visit our blog.